孟鲁司特钠联合布地奈德治疗儿童支气管哮喘的临床疗效

Analysis of Clinical Efficacy and Safety of Montelukast and Budesonide Treatment of Children with Bronchial Asthma

目的 探讨孟鲁司特钠联合布地奈德治疗儿童支气管哮喘的临床疗效。方法 选取2014年1月至2015年1月崇州市人民医院儿科收治的儿童支气管哮喘患儿120例,按随机数字表法分为对照组和观察组,各60例。其中对照组患儿给予常规治疗（止咳、平喘、化痰,抗感染等）,观察组患儿在常规治疗的基础上给予孟鲁司特钠（4~5 mg/次,每日1次）联合布地奈德（100μg/次,每日2次）治疗,治疗结束后比较两组患儿发作性喘息肺功能等指标改善情况,临床疗效及不良反应发生情况。结果 观察组患儿显效时间和临床症状恢复时间显著短于对照组[（4.3±0.8）d比（7.4±0.8）d、（2.4±0.5）d比（5.3±0.7）d,P〈0.01]。观察组患儿治疗总有效率显著高于对照组[95.0%（57/60）比68.3%（41/60）,P〈0.05];治疗后观察组日间和夜间喘息发作次数显著少于对照组[（2.9±0.7）次/月比（7.1±1.2）次/月,（2.1±0.5）次/月比（4.2±1.2）次/月]（P〈0.01）;观察组患儿治疗后用力肺活量、第一秒用力呼气量以及峰值呼气流速显著高于对照组[（2.11±0.35）L比（1.87±0.13）L、（1.31±0.41）L比（1.09±0.16）L、（312±20）mL/s比（268±26）mL/s]（P〈0.01）;两组不良反应发生率比较差异无统计学意义（P〉0.05）。结论 孟鲁司特钠联合布地奈德治疗儿童支气管哮喘临床疗效显著,且能够明显改善患者肺功能,值得临床推广应用。

Objective To investigate clinical efficacy of montelukast and budesonide treatment of chil- dren with bronchial asthma. Methods From Jan. 2014 to Jan. 2015 in Chongzhou People＇s Hospital, 120 children with bronchial asthma were included in the study and divided into a control group and an observation group according to the random number table method,60 patients in each group. The control group was treated with conventional treatment （ relieving cough, asthma, phlegm, and anti-infection etc. ）, and the observation group was treated with montelukast（4-5 mg/fime, 1 time/d） and budesorfide（ 100 p,g/time,2 times/d） on the basis of the conventional treatment. After treatment, the improvement of episodes of wheezing, lung func- tion and other indicators, and the clinical efficacy and adverse reactions of the two groups were compared. Results The effective time and clinical symptoms recovery time of the observation group were significantly shorter than the control group[（4.3＋0.8） dvs （7.4＋0.8） d,（2.4＋0.5） dvs （5.3-＋0.7） d,P〈 0. 01 ]. The therapeutic efficacy of the observation group was significantly higher than the control group [95.0% （57/60） vs 68.3% （41/60） ,P 〈0. 05 ] ;after treatment,daytime and nighttime wheezing episodes of the observation group were significantly lower than the control group[ （2. 9±0.7） times/month vs （7.1±1.2） times/month, （ 2. 1±0.5 ） times/month vs （4. 2±1.2 ） times/month ] （ P 〈 0. 01 ） ; forced vital capacity ,forced expiratory volume in one second and peak expiratory flow improvement in observation group patients after treatment were significantly higher than the control group of patients [ （ 2. 11±0. 35 ） L vs （1.87±0.13） L,（1.31±0.41） Lvs （1.09±0.16） L,（312±20） mL/svs （268±26） mL/s]（P〈 0. 01 ） ;there was no significant difference of the incidence of adverse reactions between the two groups （P 〉 0. 05 ）. Conclusion The clinical effect of montelukast and budesonide in the treatment of childhood bronchial asthma issignificant ,which can significantly improve lung function ,thus is worthy of clinical application.